To the full analysis
Gland Pharma stock: balance sheet and debt
GLAND.NSGland Pharma has a debt to equity ratio of 0.03 and an interest coverage of 45x.
Daily figure as of 13 Nov 2026
Debt / Equity
0.03
Interest coverage
45x
Current ratio
4.68
Cash & equivalents
$364.87M
Total assets
$1.33B
Equity ratio
82.8%
Goodwill
$31.23M
Plus intangible assets of $11.54M
Net debt
−$334.73M
More cash than debt
Total assets and equity ratio
How large the balance sheet of Gland Pharma Limited is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2017 | $262.93M | not reported separately | not reported separately | 84.5% | −$55.98M |
| 2018 | $311.37M | not reported separately | not reported separately | 82.3% | −$68.45M |
| 2019 | $374.51M | not reported separately | not reported separately | 81.2% | −$75.9M |
| 2020 | $434.3M | not reported separately | not reported separately | 89.2% | −$138.84M |
| 2021 | $690.46M | not reported separately | not reported separately | 90.9% | −$318.67M |
| 2022 | $832.62M | $1.33M | not split out | 91.4% | −$344.16M |
| 2023 | $932.95M | $1.24M | not split out | 90.7% | −$399.47M |
| 2024 | $1.13B | $37.68M | $25.75M | 81.8% | −$166.51M |
| 2025 | $1.19B | $37.62M | $26.38M | 81.5% | −$280.44M |
| 2026 | $1.33B | $42.78M | $31.23M | 82.8% | −$334.73M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.
Equity and debt
What the company owns and owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2017 | $56.66M | $222.12M | $677.7K | 0 |
| 2018 | $69.21M | $256.19M | $758.69K | 0 |
| 2019 | $76.61M | $304.2M | $704.8K | 0 |
| 2020 | $139.47M | $387.55M | $638.9K | 0 |
| 2021 | $319.2M | $627.45M | $530.91K | 0 |
| 2022 | $344.66M | $760.77M | $504.13K | 0 |
| 2023 | $399.95M | $845.92M | $473.3K | 0 |
| 2024 | $206.07M | $927.24M | $39.56M | 0.04 |
| 2025 | $313.78M | $972.62M | $33.35M | 0.03 |
| 2026 | $364.87M | $1.1B | $30.14M | 0.03 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.